BARTLETT, Tenn., Jan. 21, 2026 (GLOBE NEWSWIRE) -- SurgePays, Inc. (NASDAQ: SURG), a wireless and fintech point of sale company connecting subprime and underserved consumers to essential mobile and financial services, today announced the pricing of its previously announced underwritten public offering of 2,000,000 shares of common stock at a public offering price of $1.25 per share, for aggregate gross proceeds of approximately $2.5 million, prior to deducting underwriting discounts and other offering expen ...

Core Insights - Henry Schein, Inc. (HSIC) is a global provider of healthcare products and services with a market cap of $9 billion, serving dental and medical practitioners as well as alternate care sites worldwide [1][2] Financial Performance - HSIC shares have decreased 7.1% from its 52-week high of $82.49, but the stock has increased 13.7% over the past three months, outperforming the Health Care Select Sector SPDR Fund (XLV) which gained 12.1% in the same period [3] - Year-to-date, HSIC stock is up 10.7%, slightly lagging behind XLV's 11.8% increase, and has risen 4.7% over the past 52 weeks compared to XLV's 10.5% return [4] - On November 4, HSIC reported strong Q3 2025 results with adjusted EPS of $1.38, up from $1.22 a year earlier, and revenue of $3.34 billion, exceeding forecasts [5] Guidance and Analyst Outlook - The company raised its full-year 2025 adjusted EPS guidance to $4.88 - $4.96 and increased expected sales growth to 3% - 4% [5] - Despite underperformance relative to rivals like Quest Diagnostics (DGX), which returned 18.7% year-to-date, analysts maintain a moderately optimistic outlook for HSIC with a consensus rating of "Moderate Buy" and a mean price target of $77.64, representing a 1.3% premium to current levels [6]

Group 1 - The market maintains a positive outlook for the Magnificent Seven Shares, particularly Microsoft (MSFT), driven by increasing demand for AI and cloud computing, along with stable digital services revenues [1] - Invest Heroes LLC, a CIS-based research firm established in 2018, has gained recognition for its equity and fixed income research services, covering over 120 Russian, US, and Chinese stocks, and 200 Russian bonds [1] - The firm has achieved significant milestones, including participation in Refinitiv and Factset, and recognition as top analysts in the Refinitiv rating for several Russian companies [1] Group 2 - The research team at Invest Heroes LLC consists of 9 analysts, including 2 strategists, and has developed detailed business models for each company to provide forecasts that often outpace market expectations [1] - The firm serves a diverse client base, including institutional clients, asset managers, and approximately 3000 private clients [1] - Contact information for key personnel, including the CEO and Head of Research, is provided for further inquiries [1]